Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression

João Conde(Universidad de Zaragoza), Gonçalo J. L. Bernardes(University of Lisbon), Nuno L. Barbosa‐Morais(University of Lisbon), Ana Guerreiro(University of Lisbon), Tobias Weiß(University of Zurich), Michael Weller(University of Zurich), Sohyon Lee(ETH Zurich), Sandra H. Vaz(University of Lisbon), Ruth A. Pumroy(Translational Therapeutics (United States)), P. Filippakopoulos(University of Oxford), Seungil Han(Pfizer (United States)), Marta C. Marques(University of Lisbon), Vera Y. Moiseenkova‐Bell(Case Western Reserve University), Tânia Carvalho(University of Lisbon), Berend Snijder(SIB Swiss Institute of Bioinformatics), Marc Remke(Düsseldorf University Hospital), Charlotte Baker(University of Lisbon), Rafael Roque(Hospital de Santa Maria), Amrita Samanta(Translational Therapeutics (United States)), Elvira P. Leites(University of Lisbon), Francisco Corzana(Universidad de La Rioja), Tiago Rodrigues(University of Lisbon), Daniel Picard(Heidelberg University), Bernardo P. de Almeida(Research Institute of Molecular Pathology), Vanessa A. Morais(Instituto de Medicina Molecular João Lobo Antunes), Yuhang Liu(Central South University), Bárbara B. Sousa(University of Lisbon), Florian Sieglitz(University of Lisbon), Cláudia C. Faria(University of Lisbon), Maike Langini(Heidelberg University)
ACS Central Science
April 14, 2021
Cited by 63


Related Papers